Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-SELECT Dual-Target CAR-NK Cells
- Development stage
- Phase 2
- Lead developer
- Essen Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intracranial
01
Overview
EB-SELECT Dual-Target CAR-NK Cells is an investigational allogeneic, donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Essen Biotech for the treatment of advanced solid tumors. The therapy involves genetically engineering NK cells from healthy donors to express two distinct CAR constructs, allowing for the simultaneous targeting of two tumor antigens. This dual-target approach is intended to mitigate the effects of tumor antigen heterogeneity and reduce the risk of antigen escape, potentially enhancing therapeutic efficacy compared to single-target CAR therapies. The specific antigens targeted are selected for each patient based on biomarker profiling of the tumor using tissue or liquid biopsies. It is currently being evaluated in a Phase 1/2 clinical trial (NCT07410494) for a variety of relapsed or refractory solid tumors, including breast cancer, non-small cell lung cancer, and glioblastoma.
- Other names
- EB-SELECT Dual-Target CAR-NKDual-Target CAR-NK Cells
Beyond the preview
Go deeper on EB-SELECT Dual-Target CAR-NK Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-SELECT Dual-Target CAR-NK Cells.